[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344289-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344289-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","functional-loss-of-erbb-receptor-feedback-inhibitor-1-mig6-promotes-glioblastoma-tumorigenesis-by-aberrant-activation-of-epidermal-growth-factor-receptor-egfr","Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)","","Aberrant activation of EGFR drives the pathogenesis of multiple cancers, yet the functional and clinical significance of its feedback control remains incomplete. This article identifies MIG6 (ERBB receptor feedback inhibitor 1/ERRFI1) as a regulator whose loss or decreased activity disturbs the stoichiometric balance between MIG6 and EGFR. Mutations in ERRFI1 impair suppression of EGFR enzymatic activation across levels, promoting oncogenic growth. ERRFI1 mutation status and MIG6 expression are proposed as biomarkers to guide EGFR-targeted therapy, including glioblastoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/functional-loss-of-erbb-receptor-feedback-inhibitor-1-mig6-promotes-glioblastoma-tumorigenesis-by-aberrant-activation-of-epidermal-growth-factor-receptor-egfr/344289/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/functional-loss-of-erbb-receptor-feedback-inhibitor-1-mig6-promotes-glioblastoma-tumorigenesis-by-aberrant-activation-of-epidermal-growth-factor-receptor-egfr/344289.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does MIG6 play in regulating EGFR signaling?","Question",{"text":63,"@type":64},"MIG6 negatively regulates EGFR by directly inhibiting its kinase activity and promoting EGFR internalization and degradation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ERRFI1 (MIG6) mutations affect EGFR activation?",{"text":68,"@type":64},"A subset of ERRFI1 mutations shows impaired ability to suppress EGFR enzymatic activation at multiple levels.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are ERRFI1 mutation status and MIG6 expression suggested as biomarkers?",{"text":72,"@type":64},"They may help guide EGFR-targeted cancer therapies by reflecting the likelihood of abnormal EGFR activation, including in glioblastoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344289,1790093856,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)  \nSang Ah Yi 1*, Daseul Cho2,3, Sujin Kim2,3, Hyunjin Kim3, Myung Kyung Choi4, Hee Seong Choi4, Sukjin Shin2,3, Sujin Yun2,3, Ahjin Lim2,3, Jae Kyun Jeong3, Da Eun Yoon5,6 , Hye Ji Cha2, Kyoungmi Kim5,6, Jeung-Whan Han 1 , Hyun-Soo Cho4  and Jeonghee Cho2,3   \n1 Epigenome Dynamics Control Research Center, School of Pharmacy, Sungkyunkwan University, Suwon, Korea  \n2 Department of Biomedical Science & Engineering, Dankook University, Cheonan, Korea  \n3 Department of Nanobiomedical Science, Dankook University, Cheonan, Korea  \n4 Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea  \n5 Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea  \n6 Department of Physiology, Korea University College of Medicine, Seoul, Korea  \nKeywords  \nbiomarker; EGFR; glioblastoma (GBM); MIG6; targeted cancer therapy  \nCorrespondence  \nJ.-W. Han, Epigenome Dynamics Control Research Center, School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea  \nTel: +82 31 290 7716  \nE-mail: [jhhan551@skku.edu](jhhan551@skku.edu)  \nH.-S. Cho, Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea Tel: +82 2 2123 5651  \nE-mail: [hscho8@gmail.com](hscho8@gmail.com)  \nand  \nJ. Cho, Department of Biomedical Science & Engineering and Department of Nanobiomedical Science, Dankook University, Cheonan 31116, Korea  \nTel: +82 41 529 6019  \nE-mail: [jeonghee.cho@dankook.ac.kr](jeonghee.cho@dankook.ac.kr)  \nPresent address  \n*Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \nDysregulation of epidermal growth factor receptor (EGFR) is one of the most common mechanisms associated with the pathogenesis of various cancers. Mitogen-inducible gene 6 [MIG6; also known as ERBB receptor feedback inhibitor 1 (ERRFI1)], identiﬁed as a feedback inhibitor of EGFR, negatively regulates EGFR by directly inhibiting its kinase activity and facilitating its internalization, subsequently leading to degradation. Despite its proposed role as an EGFR-dependent tumor suppressor, the functional consequences and clinical relevance in cancer etiology remain incompletely understood. Here, we identify that the stoichiometric balance between MIG6 and EGFR is crucial in promoting EGFR-dependent oncogenic growth in various experimental model systems. In addition, a subset of ERRFI1 (the ofﬁcial gene symbol of MIG6) mutations exhibit impaired ability to suppress the enzymatic activation of EGFR at multiple levels. In summary, our data suggest that decreased or loss of MIG6 activity can lead to abnormal activation of EGFR, potentially contributing to cellular transformation. We propose that the mutation status of ERRFI1 and the expression levels of MIG6 can serve as additional biomarkers for guiding EGFR-targeted cancer therapies, including glioblastoma.  \nAbbreviations  \nATP, adenosine triphosphate; BRAF, B-Raf proto-oncogene; cDNA, complementary DNA; COSMIC, catalogue of somatic mutations in cancer; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERBB2, Erb-B2 receptor tyrosine kinase 2; ERKs, extracellular signal-regulated kinases; Errﬁ1, ERBB receptor feedback inhibitor 1; GBM, glioblastoma; GLICO, cerebral organoid glioma; GST, glutathione S-transferase; KRAS, Kirsten rat sarcoma virus; Mig6, mitogen-inducible gene 6; neoCOR, neoplastic cerebral organoid; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; shRNA, short hairpin RNA; STAT5, signal transducer and activator of transcription 5; TCGA, The Cancer Genome Atlas.  \nMolecular Oncology 19 (2025) 937–953 ª 2024 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.  \nThis is an open ac","cbCaiar15XrQdvZv","https://ap.wps.com/l/cbCaiar15XrQdvZv","pdf",1284989,17,"English","# Introduction\n## EGFR dysregulation and oncogenic activation mechanisms\n## MIG6 as a negative regulator of EGFR\n## Proposed significance for glioblastoma","[{\"question\":\"What role does MIG6 play in regulating EGFR signaling?\",\"answer\":\"MIG6 negatively regulates EGFR by directly inhibiting its kinase activity and promoting EGFR internalization and degradation.\"},{\"question\":\"How do ERRFI1 (MIG6) mutations affect EGFR activation?\",\"answer\":\"A subset of ERRFI1 mutations shows impaired ability to suppress EGFR enzymatic activation at multiple levels.\"},{\"question\":\"Why are ERRFI1 mutation status and MIG6 expression suggested as biomarkers?\",\"answer\":\"They may help guide EGFR-targeted cancer therapies by reflecting the likelihood of abnormal EGFR activation, including in glioblastoma.\"}]","Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR) | PDF",1790053352,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de6f20e10fcb0f3048d402b4d46efd2e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf96dc4af83574d9c72da335a962c534.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44850e39d68473394077b44682d4c783.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/746db55518b810f806080a3b9d4074a8.webp",980,1287]